The use of the myocardial cytoprotector trimetazidine in a patient with angina as an example of off-label use
https://doi.org/10.15829/1728-8800-2019-6-116-120
Abstract
The clinical case of the successful use of the myocardial cytoprotector trimetazidine as a universal anti-ischemic agent in a patient with hemodynamic angina due to myocardial bridging is described. The pathogenetic rationale for this prescription is presented.
About the Authors
O. V. Tsygankova
Scientific Research Institute of Therapy and Preventive Medicine, branch of the Federal Research Center Institute of Cytology and Genetics; Novosibirsk State Medical University
Russian Federation
Russian Federation
Novosibirsk.
L. D. Latyntseva
Scientific Research Institute of Therapy and Preventive Medicine, branch of the Federal Research Center Institute of Cytology and Genetics
Russian Federation
Novosibirsk.
Russian Federation
Novosibirsk.
T. I. Batluk
Scientific Research Institute of Therapy and Preventive Medicine, branch of the Federal Research Center Institute of Cytology and Genetics
Russian Federation
Novosibirsk.
Russian Federation
Novosibirsk.
D. Yu. Platonov
Tver State Medical University
Russian Federation
Russian Federation
Tver.
N. M. Akhmedzhanov
National Medical Research Center for Preventive Medicine
Russian Federation
Russian Federation
Moscow.
References
1. Tsygankova OV, Nikolayev KYu, Fedorova EL, Bondareva ZG. Exchange of sex hormonesin the body of a man through the prism of cardio-vascular risk. Atherosclerosis and dyslipidemia. 2014;1(14):17-25. (In Russ.)
2. Myocardial defense in myocardial revascularization: focus on Preductal MB®. Talk with professor Yury Mihajlovich Lopatin. Meditsinskii sovet. 2013;(9):98-100. (In Russ.)
3. Michaelides AP, Spiropoulos K, Dimopoulos K, et al. Antianginal Efficacy of the Combination of Trimetazidine-Propranolol Compared with Isosorbide Dinitrate-Propranolol in Patients with Stable Angina. Clin Drug Invest. 1997;13:8-14. doi:10.2165/00044011-199713010-00002.
4. 2014 ESC/EACTS Guidelines on myocardial revascularization. The Task Force on 7. Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Russ J Cardiol. 2015;(2):5-81. (In Russ.)
5. Egorov IV. Stenosis of the aortic estuary: features of antianginal treatment. Consilium Medicum. 2009;01:88-93. (In Russ.)
6. Trukhan DI, Mazurov AL, Davydov EL. Myocardial cytoprotector trimetazidine MB — preparat increases the effectiveness of treatment of chronic heart failure and coronary heart disease. Meditsinskii sovet. 2017;(7):75-83. (In Russ.)
7. Vitale C, Marazzi G, Pelliccia F, et al. Trimetazidine improves exercise performance in patients with peripheral arterial disease. Pharmacol Res. 2011 63:278-83. doi:10.1016/j.phrs.2011.01.003.
Review
For citations:
Tsygankova O.V., Latyntseva L.D., Batluk T.I., Platonov D.Yu., Akhmedzhanov N.M. The use of the myocardial cytoprotector trimetazidine in a patient with angina as an example of off-label use. Cardiovascular Therapy and Prevention. 2019;18(6):116-120. (In Russ.) https://doi.org/10.15829/1728-8800-2019-6-116-120
Views:
691
Email this article 
